Celltrion Pharm Inc.
068760 | KO
Overview
Corporate Details
- ISIN(s):
- KR7068760008
- LEI:
- Country:
- South Korea
- Address:
- 충청북도 청주시 청원구 오창읍 2산단로 82셀트리온제약, 청주시
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-29 00:00 |
Governance Information
대규모기업집단현황공시[분기별공시(개별회사용)]
|
Korean | 8.9 KB | ||
| 2025-08-14 00:00 |
Regulatory Filings
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
|
Korean | 11.1 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 2.6 MB | ||
| 2025-06-23 00:00 |
Major Shareholding Notification
[기재정정]대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
|
Korean | 135.3 KB | ||
| 2025-05-30 00:00 |
Major Shareholding Notification
대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
|
Korean | 100.8 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.4 MB | ||
| 2025-05-07 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 25.8 KB | ||
| 2025-04-10 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.9 KB | ||
| 2025-04-10 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 252.0 KB | ||
| 2025-04-04 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-04-04 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-04-04 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-04-04 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.9 KB | ||
| 2025-04-04 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-04-04 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB |
Automate Your Workflow. Get a real-time feed of all Celltrion Pharm Inc. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Celltrion Pharm Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Celltrion Pharm Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Developing long-acting therapies for rare allergic and immunologic diseases like HAE.
United States of America
ATXS
United States of America
ATXS
Clinical-stage biopharma creating novel psychedelic drugs for mental health disorders.
United States of America
ATAI
United States of America
ATAI
A clinical-stage biopharma developing oral antiviral therapies for viruses like Hepatitis C.
United States of America
AVIR
United States of America
AVIR
Developing small-molecule therapies to slow neurodegeneration in diseases like Alzheimer's.
United States of America
ATHA
United States of America
ATHA
Clinical-stage biopharma developing (Z)-endoxifen for breast cancer treatment and prevention.
United States of America
ATOS
United States of America
ATOS
Developing novel medicines for fibrosis and inflammation using tRNA synthetase biology.
United States of America
ATYR
United States of America
ATYR
Developing virus-like therapies to selectively destroy solid tumors in ocular & urologic oncology.
United States of America
AURA
United States of America
AURA
Biopharma developing therapies for autoimmune and kidney diseases like lupus nephritis.
United States of America
AUPH
United States of America
AUPH
A global producer and seller of medical and recreational cannabis and derivative products.
United States of America
ACB
United States of America
ACB
Develops programmed CAR T-cell therapies for cancer and autoimmune diseases.
United States of America
AUTL
United States of America
AUTL